Drug Profile


Alternative Names: MSI-1436; Produlestan; Trodulamine

Latest Information Update: 12 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genaera Corporation
  • Developer DepYmed; Genaera Corporation
  • Class Anorectics; Antihyperglycaemics; Antivirals; Biogenic amines; Cholestanes; Obesity therapies; Polyamines
  • Mechanism of Action Adrenergic uptake inhibitors; Apoptosis stimulants; Dopamine uptake inhibitors; Neuropeptide Y modulators; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Discontinued Diabetes mellitus; HIV infections; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Breast cancer (Metastatic disease) in USA (IV) (NCT02524951)
  • 20 Aug 2015 North Shore-Long Island Jewish Health System plans a phase I trial for Breast cancer (Metastatic disease) in USA (NCT02524951)
  • 09 Feb 2015 Discontinued - Preclinical for Diabetes mellitus in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top